Sihuan Pharmaceutical Holdings Group (0460) AI Stock Analysis

• Market Cap: HK$14.74B
• Dividend Yield: 0.87%
• Average Volume (3M): 37.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: 19.21%
• EPS Growth: -115.91%
• Country: HK
• Employees: 2,667
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.01
• Shares Outstanding: 9,329,999,000
• 10 Day Avg. Volume: 24,963,024
• 30 Day Avg. Volume: 37,542,935
• PEG Ratio: -0.09
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 3.02
• P/FCF Ratio: 99.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: HK$1.50 ▲(13.64% Upside)

The score is held back primarily by weak financial performance—declining revenue, ongoing losses, and unstable/negative free cash flow. Technicals are comparatively stronger with price above major moving averages and a positive MACD, but RSI near 70 indicates momentum may be stretched. Valuation is also constrained by the loss-making profile despite a high dividend yield.

Positive Factors

Therapeutic diversification & proprietary drugs

Broad exposure across cardiovascular, CNS and anti-infection markets plus proprietary products reduces single-product risk and supports multiple revenue streams. This durable portfolio mix helps steady revenue when individual drug lifecycles fluctuate and aids long-term commercialization potential.

Established distribution and partnerships

Deep relationships with hospitals, clinics and distributors create durable go-to-market channels for both RX and OTC products in China. These partnerships lower commercialization friction for new launches, sustain product turnover, and provide structural support for scaling sales across geographies and care settings.

Low financial leverage

A low debt profile reduces refinancing and interest-rate risk, preserving strategic flexibility. That balance-sheet room supports continued R&D investment or working-capital management during cyclical revenue weakness, enabling the company to pursue recovery without immediate solvency pressure.

Negative Factors

Multi-year revenue decline

A sustained fall in top-line over several years signals weakening market share, potential product obsolescence, or commercialization gaps. That trend undermines scale economics, strains R&D payback, and makes profitable growth harder absent successful new launches or market re-expansion initiatives.

Persistent losses and negative margins

Ongoing net losses and negative operating margins indicate structural profitability issues—whether pricing, cost base, or product mix. Without sustained margin recovery, the company will struggle to self-fund innovation and operations, increasing reliance on external capital and constraining strategic options.

Volatile and negative cash flow

Erratic operating cash generation and recent negative free cash flow create persistent liquidity risk and limit ability to invest in R&D or commercial expansion. Structural cash volatility raises the probability of management needing external financing, diluting shareholders or forcing cost cuts that impair long-term growth.

Sihuan Pharmaceutical Holdings Group Business Overview & Revenue Model

Company Description

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.

How the Company Makes Money

Sihuan Pharmaceutical generates revenue through the sale of its pharmaceutical products, which are distributed to hospitals, clinics, and pharmacies across China and other markets. The company has several key revenue streams including prescription drugs, over-the-counter medications, and injectable products. A significant portion of its income is derived from its proprietary drugs that address common health issues, particularly in the cardiovascular and central nervous system sectors. Additionally, Sihuan has established partnerships with various healthcare providers and distributors, enhancing its market reach and sales capabilities. The company also focuses on expanding its product portfolio through ongoing research and development, which is expected to drive future growth and revenue generation.

Sihuan Pharmaceutical Holdings Group Financial Statement Overview

Summary

Revenue has declined materially (about 3.04B in 2021 to about 1.90B in 2024) with consistent net losses and negative EBIT/EBITDA margins, indicating weak profitability and operational pressure. Cash flow is volatile with recent negative free cash flow and inconsistent operating cash flow, raising liquidity risk. Balance sheet leverage is low, but equity and assets have been shrinking.

Income Statement

Sihuan Pharmaceutical's income statement reflects significant challenges in recent years. The company experienced a substantial decline in revenue from 2021 to 2024, with revenue decreasing from approximately 3.04 billion to 1.90 billion. Gross profit margins have remained relatively stable, but consistent net losses have been reported, indicating profitability issues. The EBIT and EBITDA margins have turned negative, suggesting operational inefficiencies and a need for cost management improvements.

Balance Sheet

The balance sheet indicates a mixed financial position. The company's debt-to-equity ratio is low, which is positive, but stockholders' equity has decreased over time. The equity ratio remains adequate, reflecting a stable asset base. However, the decline in total assets and stockholders' equity raises concerns about long-term financial stability.

Cash Flow

Cash flow analysis shows significant volatility. The company's free cash flow has fluctuated, with recent years showing negative free cash flow, indicating potential liquidity issues. Operating cash flow has also been inconsistent, with the most recent period showing zero, highlighting challenges in generating cash from operations. These factors suggest a need for improved cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.10B	1.90B	1.86B	2.18B	3.04B	2.46B
Gross Profit	1.39B	1.24B	1.30B	1.49B	2.43B	1.91B
EBITDA	-18.36M	-208.66M	334.31M	-1.54B	931.69M	714.06M
Net Income	-80.64M	-216.66M	-54.02M	-1.91B	416.51M	473.38M
Balance Sheet
Total Assets	10.62B	10.53B	11.54B	12.14B	14.50B	13.04B
Cash, Cash Equivalents and Short-Term Investments	3.60B	3.63B	4.48B	4.79B	5.79B	4.94B
Total Debt	1.03B	942.76M	1.26B	1.29B	1.08B	755.05M
Total Liabilities	5.68B	5.58B	6.40B	6.50B	5.35B	3.10B
Stockholders Equity	4.38B	4.37B	4.43B	4.74B	8.28B	9.19B
Cash Flow
Free Cash Flow	62.70M	57.51M	-95.93M	-355.97M	64.28M	-279.51M
Operating Cash Flow	112.15M	243.89M	199.49M	46.49M	665.29M	227.13M
Investing Cash Flow	368.40M	758.24M	169.88M	-1.66B	-337.57M	-924.78M
Financing Cash Flow	-1.23B	-1.26B	-419.56M	-238.93M	750.66M	184.54M

Sihuan Pharmaceutical Holdings Group Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0460, the sentiment is Positive. The current price of 1.32 is below the 20-day moving average (MA) of 1.38, below the 50-day MA of 1.33, and above the 200-day MA of 1.27, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 77.77 is Negative, neither overbought nor oversold. The STOCH value of 87.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0460.

Sihuan Pharmaceutical Holdings Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1681	72 Outperform	HK$14.85B	13.99	25.92%	3.93%	19.05%	13.68%
0719	58 Neutral	HK$10.33B	11.71	7.48%	4.47%	1.65%	-16.38%
0570	54 Neutral	HK$10.37B	-36.27	-1.26%	3.66%	-9.58%	-128.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0460	50 Neutral	HK$14.74B	-166.32	-1.87%	0.87%	19.21%	-115.91%
6185	47 Neutral	HK$13.51B	-57.08	-2.79%	―	29.21%	80.37%

Sihuan Pharmaceutical Holdings Group Corporate Events

Sihuan Pharmaceutical Expands PLLA Filler Range With Six New NMPA-Approved Specifications

Sihuan Pharmaceutical announced that its subsidiary Meiyan Space Biotechnology has received National Medical Products Administration approval in China for six new specifications of its polylactic acid (PLLA) facial filler, adding 60mg to 130mg formats to the existing 45mg, 75mg and 150mg portfolio. The broader dosage range is designed to more precisely match varying anti-aging needs from early to severe aging, enhance physicians’ operational flexibility by allowing finer adjustment of dilution and dosing, and strengthen Sihuan’s competitive edge in the fast‑growing regenerative medical aesthetics market by deepening its differentiated product matrix alongside PCL fillers and energy-based devices. Management positions the move as supporting an industry shift toward personalized, high-quality aesthetic treatments and expects to leverage its nationwide institutional coverage to accelerate commercialization, potentially driving the medical aesthetics segment into a new phase of scale growth.

The most recent analyst rating on (HK:0460) stock is a Sell with a HK$1.00 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

Sihuan Pharmaceutical Launches Share Buyback Amid Pivotal Turnaround and Aesthetics-Led Growth

Sihuan Pharmaceutical has launched a share repurchase program under its existing mandate, buying back 8 million shares on the market at an average price of HK$1.2511 per share, equivalent to about 0.0874% of its issued share capital, with plans to hold these as treasury shares for future sale or transfer. The board frames the move as aligned with shareholder interests amid a pivotal turnaround year marked by a return to profit, stronger margins, and rapid expansion of its medical aesthetics franchise—now offering a full portfolio from botulinum toxin to aesthetic devices and expanding globally via a Swiss acquisition—alongside notable progress in its biopharmaceutical pipeline, including multiple drug approvals, NRDL inclusion, FDA Fast Track status, and the successful Hong Kong listing of subsidiary Xuanzhu Biopharm, which has boosted equity value, eased R&D funding pressure, and supports a shift into a new phase of higher-quality, growth-focused development.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

Sihuan Pharma Buys 9 Million Shares for Award Scheme as Dual-Drive Strategy Advances

Sihuan Pharmaceutical Holdings Group has disclosed that the trustee of its 2022 share award scheme purchased 9 million shares on the market on 18 December 2025, representing about 0.0983% of its issued share capital, at an average price of roughly HK$1.2271 per share. The board views this share purchase as a move to strengthen its equity base and incentivise its team, supporting the company’s current growth phase and long-term strategy. Management highlighted strong progress in 2025 under its dual-drive strategy of innovative drugs and global medical aesthetics expansion, including full-value-chain breakthroughs at core subsidiaries Xuanzhu Biopharm and Huisheng Biopharm—from R&D and launches to inclusion in China’s National Reimbursement Drug List—alongside rapid commercialization of self-developed regenerative medical aesthetics products and entry into the European market via its investment in Swiss firm Suisselle, developments that the company believes will enhance competitiveness, open new growth avenues, and bolster shareholder value over time.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

Sihuan Pharmaceutical’s Anjiuwei Secures Spot in 2025 NRDL, Boosting Market Prospects

Sihuan Pharmaceutical Holdings Group announced the successful renewal and inclusion of its innovative drug, Anjiuwei, in the 2025 National Reimbursement Drug List (NRDL) in China. This renewal is expected to stabilize market sales and enhance the drug’s penetration, supporting its long-term growth. Anjiuwei, developed by Xuanzhu Biopharm, a Sihuan subsidiary, is a proton pump inhibitor approved for treating duodenal ulcers. Its innovative design makes it a safer option for patients with multiple medications or renal insufficiency, filling a gap in China’s domestic market for such treatments.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

Sihuan Pharmaceutical’s Innovative Drug Xuanyuening Gains NRDL Inclusion

Sihuan Pharmaceutical Holdings Group Ltd. announced that its innovative drug, Bireociclib Tablets (brand name: Xuanyuening), developed by its subsidiary Xuanzhu Biopharmaceutical Co., Ltd., has been included in the National Reimbursement Drug List (NRDL) for 2025. This inclusion is expected to enhance the drug’s affordability and accessibility, significantly impacting Xuanzhu Biopharm’s market presence and sales. Bireociclib, a novel CDK2/4/6 inhibitor, offers advantages in treating advanced or metastatic breast cancer with reduced toxicity. The drug’s inclusion in the NRDL is anticipated to bolster Xuanzhu Biopharm’s long-term business development and market expansion efforts.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

Sihuan Pharmaceutical’s Xuanzhu Biopharma Plans H Share Full Circulation

Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharma, is considering the implementation of H share full circulation. This involves converting approximately 68.97% of its unlisted shares into H shares, pending approval from the China Securities Regulatory Commission. The move is aimed at enhancing the liquidity and marketability of Xuanzhu Biopharma’s shares, although the listing details on the Hong Kong Stock Exchange are yet to be finalized.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

Sihuan Pharmaceutical Partners with Abalone Bio for Innovative Obesity Therapy

Sihuan Pharmaceutical Holdings Group Ltd. has signed a cooperation agreement with U.S.-based Abalone Bio to jointly develop a new-generation innovative therapy for weight loss and muscle gain. This collaboration aims to advance research in targeting metabolism-related G protein-coupled receptors (GPCRs) to improve energy expenditure safely and effectively. The partnership leverages Abalone’s proprietary technology and Sihuan’s R&D resources to address current limitations in obesity treatments and enhance the company’s strategic position in the GPCR target field. This agreement marks a significant step in Sihuan’s strategy to deepen its involvement in the GPCR field, following its previous investment in DJS Antibodies.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

Sihuan Pharmaceutical’s NG-350A Receives FDA Fast Track Designation

Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharm, has received Fast Track designation from the U.S. FDA for NG-350A, a treatment for mismatch repair-proficient locally advanced rectal cancer. This designation is significant as it expedites the development and approval process for drugs addressing unmet medical needs. NG-350A, developed in collaboration with Akamis Bio Ltd., is currently undergoing Phase Ib clinical trials and has shown promising results in safety and efficacy. This advancement strengthens Sihuan Pharmaceutical’s position in the oncology sector and highlights its commitment to addressing major clinical needs.

The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.